New combo therapy aims to shrink stomach cancer spread

NCT ID NCT07304258

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a treatment plan for people with stomach cancer that has spread to the lining of the abdomen. The plan combines heated chemotherapy directly in the abdomen (HIPEC), standard chemotherapy, and an immunotherapy drug called tislelizumab. The goal is to see if this combination can shrink the cancer enough to allow for complete surgical removal. About 30 adults who have not had prior treatment will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER PERITONEAL METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Fourth Affiliated Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••